|
Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A.
Evaluation of the effect of Alfuprost® MR on detrusor thickness and bladder mass in patients with detrusor hypertrophy caused by benign prostatic hyperplasia
|
№6 / 2023
|
|
A.O. Morozov, E.Yu. Timofeeva, A.Yu. Suvorov, S.N. Allenov, L.G. Spivak
Efficiency and safety of the drug Adenoprosin in patients with prostate diseases. Systematic review and meta-analysis
|
№5 / 2023
|
|
S.N. Volkov, R.K. Mikheev, O.R. Grigoryan, E.N. Andreeva
The comparative analysis of surgical procedures a in patients with benign prostatic hyperplasia and type 2 diabetes mellitus
|
№4 / 2023
|
|
V.N. Pavlov, A.A. Kazikhinurov, R.A. Kazikhinurov, S.Sh. Sabirzyanov, Yu.D. Saleeva, K.A. Kazikhinurova
The use of prostate extract preparations in patients after transurethral resection of prostate for its benign hyperplasia
|
№6 / 2022
|
|
A.V. Kuzmenko, V.V. Kuzmenko, T.A. Gyaurgiev, G.A. Kuzmenko
Evaluation of long-term results of the use of entomological drug in the combination therapy of patients with benign prostatic hyperplasia and chronic prostatitis
|
№6 / 2022
|
|
V.A. Malkhasyan, S.V. Kotov, I.E. Mamaev, S.V. Belomytcev, R.A. Perov, S.A. Pulbere, A.I. Volnukhin, D.U. Pushkar
Efficacy and safety of intermittent catheterization for acute urinary retention: a prospective comparative randomized study
|
№6 / 2022
|
|
A.V. Kuzmenko, V.V. Kuzmenko, T.A. Gyaurgiev
Postcovid complications in urology. prevention
|
№3 / 2022
|
|
A.V. Kuzmenko, T.A. Gyaurgiev, G.A. Kuzmenko
Our experience of using hexane extract of Serenoa Repens fruit (Permixone) in the treatment of LUTS in clinical practice
|
№2 / 2022
|
|
M.B. Chibichyan, E.A. Chernogubova, A.V. Avetyan, T.O. Lapteva, I.A. Pavlenko, M.I. Kogan
The role of angiotensin-converting enzyme and angiotensin ii receptors of the second type in the pathogenesis of proliferative diseases of the prostate
|
№1 / 2022
|
|
A.V. Kuzmenko, V.V. Kuzmenko, T.A. Gyaurgiev, Yu.Yu. Vinnik
An observational randomized study of the efficacy and safety of the drug Longidase®, vaginal and rectal suppositories 3000 iu in the treatment of patients with symptoms of the lower urinary tract on the background of benign prostatic hyperplasia
|
№6 / 2021
|
|
A.V. Kuzmenko, Yu.Yu. Vinnik, V.V. Kuzmenko, T.A. Gyaurgiev
The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis
|
№3 / 2021
|
|
S.V. Kotov, A.D. Bolotov, S.V. Belomyttsev,
D.N. Surenkov, A.V. Vorobyova
Multicenter randomized study
of bovhyalu-ronidase azoximer (Longidaza®)
in men after transuretral resection
of the prostate
|
№3 / 2021
|
Русский
